West Nile virus (WNV)-induced encephalitis has been a public health concern in North America over the past decade. No therapeutics or vaccines are available for human use. Studies in animal models have provided important information for investigations of WNV pathogenesis and the host immune response in humans. This article will give an overview of the role of γδ T cells, one of the non-classical T cell subsets in the murine model of WNV encephalitis.
Introduction
West Nile virus (WNV), a plus-sense, single-stranded neurotropic flavivirus, is now the most widely distributed arbovirus in the world, occurring on all continents except Antarctica (Kramer et al., 2008) . It was originally isolated in Africa and later caused epidemics with mainly febrile illness in humans in Europe, Africa, the Middle East, and parts of Asia. In North America, a more virulent WNV strain was detected in 1999 and has caused annual outbreaks of viral encephalitis (Campbell et al., 2002; Pletnev et al., 2006) . WNV is maintained in an enzootic cycle that involves mosquitoes and birds, with humans and horses as incidental hosts. Human infection results primarily from mosquito bites (Campbell et al., 2002) . Additionally, blood transfusion, organ transplantation, breast feeding and in utero or occupational exposure were reported to be associated with WNV transmission in humans (Anon., 2002a (Anon., , 2002b Charatan, 2002; Alpert et al., 2003) . WNV infection of the central nervous system (CNS, neuroinvasive disease) commonly presents as encephalitis, meningitis or acute flaccid paralysis. Those at highest risk of developing WNV-induced encephalitis are the elderly (> 70 years) and immuno-suppressed persons. At present, there is no specific therapeutic agent for treatment of the infection or an approved vaccine for its prevention. Journal of Neuroimmunology 240-241 (2011) 22-27 
